[间碘苄胍闪烁扫描术在神经母细胞瘤诊断及随访中的应用。附16例报告]
[Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases].
作者信息
Hammami Hatem, Hassine Latifa, Mhiri Aida, Sellem Ali, Oubich Fayçal, Gharssallah Lamia, Barsaoui Sihem, Ben Brahim Habib
机构信息
Service de Médecine Nucléaire, Hôpital Militaire de Tunis, Tunis
出版信息
Tunis Med. 2007 May;85(5):413-6.
AIMS
The aim of this study is to evaluate meta-iodo-benzyl-guanidine scintigraphy in the diagnosis and the management of neuroblastoma.
PATIENTS AND METHODS
betwen september 1999 and jun 2004, 16 children aging from 4 months to 6 years, with neuroblastoma, underwent mIBG scintigraphy in military hospital nuclear medicine department.
RESULTS
23 mIBG scans were done. The exam was indicated for the initial staging in 7 cases, to evaluate chemotherapy or surgery in 12 cases and to seek for reccurences in 3 cases. The sensitivity of mIBG was 57% in the detection of the primary tumor, 100% for liver metastases and 67% for medullar involvement.
CONCLUSION
mIBG scintigraphy should be a standard in the initial staging of neuroblastoma and in evaluating therapy response.
目的
本研究旨在评估间碘苄胍闪烁扫描术在神经母细胞瘤诊断及治疗中的应用。
患者与方法
1999年9月至2004年6月期间，16例年龄在4个月至6岁的神经母细胞瘤患儿在军队医院核医学科接受了间碘苄胍闪烁扫描术。
结果
共进行了23次间碘苄胍扫描。该检查用于7例患者的初始分期，12例患者评估化疗或手术情况，3例患者用于寻找复发。间碘苄胍检测原发肿瘤的敏感性为57%，肝转移的敏感性为100%，骨髓受累的敏感性为67%。
结论
间碘苄胍闪烁扫描术应成为神经母细胞瘤初始分期及评估治疗反应的标准方法。
Zotero 插件